London, England, United Kingdom The main office of represented Corporate Investor is situated in the London. The company was established in Europe in United Kingdom.
The higher amount of exits for fund were in 2019. The common things for fund are deals in the range of 50 - 100 millions dollars. The fund is generally included in less than 2 deals every year. Opposing the other organizations, this UBS Asset Management works on 11 percentage points more the average amount of lead investments. The top activity for fund was in 2016.
The usual cause for the fund is to invest in rounds with 6-7 partakers. Despite the UBS Asset Management, startups are often financed by MPM Capital, Taiho Ventures, New Leaf Venture Partners. The meaningful sponsors for the fund in investment in the same round are MPM Capital, Taiho Ventures, New Leaf Venture Partners. In the next rounds fund is usually obtained by MPM Capital, Taiho Ventures, New Leaf Venture Partners.
Among the most popular portfolio startups of the fund, we may highlight TCR2, Harpoon Therapeutics. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup needs to be aged 2-3 years to get the investment from the fund. The fund has no specific favorite in a number of founders of portfolio startups. Among the most popular fund investment industries, there are Life Science, Therapeutics.
Related Funds
| Fund Name | Location |
| Altira Group | Colorado, Denver, United States |
| Arix Bioscience | England, London, United Kingdom |
| Edison International | California, Rosemead, United States |
| Estlander & Partners | - |
| Europ@web | Boulogne-Billancourt, France, Ile-de-France |
| Fi Capital | Beijing, Beijing, China |
| Industrial Investment Corporation | - |
| Long Focus Capital | - |
| Modernization and Technology Development Fund | - |
| Mustedanagic & Plott Brothers GbR | - |
| Praktikerinvest | Stockholm, Stockholm County, Sweden |
| Septeni | Chiyoda, Japan |
| Shoutou Zichan | China, Guangdong, Zhuhai |
| Tactics II Stem Cell Ventures | Illinois, Northbrook, United States |
| The Foundry | California, Menlo Park, United States |
| Times Business Solutions Limited | - |
| Zhejiang Chengzhang Wenchuang Zichan | China, Hangzhou, Zhejiang |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Harpoon Therapeutics | $70M | 12 Nov 2018 | South San Francisco, California, United States | ||
TCR2 | $125M | 21 Mar 2018 | Cambridge, Massachusetts, United States | ||
Harpoon Therapeutics | $45M | 25 May 2017 | South San Francisco, California, United States | ||
TCR2 | $44M | 08 Dec 2016 | Cambridge, Massachusetts, United States | ||
Harpoon Therapeutics | $15M | 01 Apr 2016 | South San Francisco, California, United States |
– Eat Just, Inc. announced that its GOOD Meat division has secured $170m in new funding.
– With this transaction, GOOD Meat becomes a subsidiary of Eat Just, which announced a $200m fundraise in March.
– The latest investment from funds managed by UBS O’Connor, a hedge fund manager within UBS Asset Management, Graphene Ventures, K3 Ventures and others, will be used to increase capacity and accelerate research and development for high-quality, real meat without slaughter.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Harpoon Therapeutics | $70M | 12 Nov 2018 | South San Francisco, California, United States | ||
TCR2 | $125M | 21 Mar 2018 | Cambridge, Massachusetts, United States | ||
Harpoon Therapeutics | $45M | 25 May 2017 | South San Francisco, California, United States | ||
TCR2 | $44M | 08 Dec 2016 | Cambridge, Massachusetts, United States | ||
Harpoon Therapeutics | $15M | 01 Apr 2016 | South San Francisco, California, United States |
